Abstracts Archive - Page 1403 of 2425 - ACR Meeting Abstracts

Abstract Number: 2962 • 2017 ACR/ARHP Annual Meeting
MRI Results Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: Results from a Randomized Controlled Trial
Charles Peterfy¹, Joel Kremer², William F C Rigby³, Nora Singer⁴, Christine Birchwood⁵, Darcy Gill⁵, William Reiss⁵, Jinglan Pei⁵ and Margaret Michalska⁵, ¹Spire Sciences, Inc., Boca Raton, FL, ²Albany Medical College, Albany, NY, ³Geisel School of Medicine at Dartmouth, Lebanon, NH, ⁴Case Western Reserve University School of Medicine, Cleveland, OH, ⁵Genentech, Inc., South San Francisco, CA
Background/Purpose: Although previous studies have established the efficacy of tocilizumab (TCZ) initiated as monotherapy (MONO) for the treatment of rheumatoid arthritis (RA),1,2 changes in active…
Abstract Number: 2963 • 2017 ACR/ARHP Annual Meeting
Sirukumab Improves Synovial Vascularity As Measured By Power Doppler Sonography in Rheumatoid Arthritis Patients from As Early As Week 4 in a Phase 3 Trial
Bidisha Dasgupta¹, Kristen Sweet¹, Dick DeVries², Benjamin Hsu¹, Ian Gourley¹, Matthew Loza¹ and Peter C. Taylor³, ¹Janssen Research & Development, LLC, Spring House, PA, ²Janssen Biologics Europe, Leiden, Netherlands, ³Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom
Background/Purpose: Ultrasound (US) is an established non-invasive tool for sensitively assessing disease activity at the individual‐joint level in rheumatoid arthritis (RA). Synovial thickness is detectable…
Abstract Number: 2964 • 2017 ACR/ARHP Annual Meeting
Structural Damage in Patients with Very Early RA Is Predicted with Clinical Measures of Baseline Disease Activity: DAS28 (CRP), SDAI, M-DAS28 and RAPID3 but Not CDAI
Edward C. Keystone¹, H Ahmad², Yusuf Yazici³, X Liu² and MJ Bergman⁴, ¹University of Toronto, Toronto, ON, Canada, ²Bristol-Myers Squibb, Princeton, NJ, ³New York University School of Medicine, New York, NY, ⁴Drexel University College of Medicine, Philadelphia, PA
Background/Purpose: Clinicians rely on time-efficient, validated disease activity assessments to help accurately predict disease progression in patients with RA. The utility of the Routine Assessment…
Abstract Number: 2965 • 2017 ACR/ARHP Annual Meeting
Non-Invasive Imaging Methods for Evaluating the Cardiovascular Involvement in Patients with Rheumatoid Arthritis before and after 18 Months of Treatment with Anti-TNF Drugs
Fabiola Atzeni¹, Luigi Gianturco², Laura Boccassini³, Piercarlo Sarzi-Puttini³ and Maurizio Turiel⁴, ¹Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milano, Italy, ²Beato Matteo” Hospital, GSD Foundation, Vigevano, Italy, Vigevano, Italy, ³Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milan, Italy, ⁴IRCCS, Galeazzi Orthopedic Institute, Dept. Biomedical Sciences for Health, University of Milan, Milan, Italy
Background/Purpose: The aim of this study was to evaluate left ventricular myocardial function with two- dimensional speckle tracking echocardiography (STE), in addition to conventional Doppler…
Abstract Number: 2966 • 2017 ACR/ARHP Annual Meeting
Impact of Tofacitinib Treatment Compared with Placebo or Methotrexate on Cardiovascular Risk Scores in Six Phase 3 Randomized Controlled Trials
Michael Nurmohamed¹, Ernest Choy², Christina Charles-Schoeman³, George Kitas⁴, Paola Accossato⁵, Piotr Szczypa⁶, Konstantina Chouchouli⁷, Tatjana Lukic⁸ and Pinaki Biswas⁸, ¹VU University Medical Centre, Amsterdam, Netherlands, ²CREATE Center, Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom, ³University of California, Los Angeles, Los Angeles, CA, ⁴Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, ⁵Pfizer S.r.l, Rome, Italy, ⁶Pfizer Ltd, Walton Oaks, United Kingdom, ⁷Pfizer Hellas S.A, Neo Psychiko, Greece, ⁸Pfizer Inc, New York, NY
Background/Purpose: Patients (pts) with RA are at increased risk of myocardial infarction and stroke not fully explained by usual cardiovascular (CV) risk factors. Tofacitinib is…
Abstract Number: 2967 • 2017 ACR/ARHP Annual Meeting
Adding Ultrasound to the Treat-to-Target Strategy Shows No Benefit in Achievement of Remission: Results from the Biodam Cohort
Alexandre Sepriano¹, Sofia Ramiro², Robert B.M. Landewé³, Désirée van der Heijde¹, Sarah Ohrndorf⁴, Oliver FitzGerald⁵, Marina Backhaus⁶, Maggie Larche⁷, Joanne Homik⁸, Alain Saraux⁹, Hilde B. Hammer¹⁰, Lene Terslev¹¹, Mikkel Østergaard¹¹, Gerd R. Burmester¹², Bernard Combe¹³, Maxime Dougados¹⁴, Carol A Hitchon¹⁵, Gilles Boire¹⁶, Robert G. Lambert⁸, Rana Dadashova¹⁷, Joel Paschke¹⁸, Edna Hutchings¹⁷ and Walter P. Maksymowych¹⁷, ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ³University of Amsterdam and Atrium Medical Center, Amsterdam, Netherlands, ⁴Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ⁵ASRI, Dublin, Ireland, Dublin, Ireland, ⁶Rheumatology/Immunology, Charite University Hospital, Berlin, Germany, ⁷Medicine, McMaster University, Hamilton, ON, Canada, ⁸University of Alberta, Edmonton, AB, Canada, ⁹Rheumatology Department, Rheumatology Department, CHU de la Cavale Blanche, Brest, France, Brest Cedex, France, ¹⁰Dept. of Rheumtology, Diakonhjemmet Hospital, Oslo, Norway, ¹¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, ¹²Department of Rheumatology and Clinical Immunolgy, Charité University Hospital, Berlin, Germany, ¹³Rheumatology, Lapeyronie Hospital, Montpellier I university, Montpellier, France, ¹⁴Paris-Descartes University,, Paris, France, ¹⁵University of Manitoba, Winnipeg, MB, Canada, ¹⁶Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ¹⁷CaRE Arthritis, Edmonton, AB, Canada, ¹⁸CARE Arthritis, Edmonton, AB, Canada
Background/Purpose: While, a Treat-to-Target strategy (T2T), treating patients with rheumatoid arthritis (RA) towards a certain target (eg. clinical remission; T2T-REM), is highly recommended, several patients…
Abstract Number: 2968 • 2017 ACR/ARHP Annual Meeting
Less Fatigue in Psoriatic Arthritis after High Intensity Interval Training. a Randomized Controlled Trial
Ruth Stoklund Thomsen¹, Tom Ivar Lund Nilsen², Glenn Haugeberg³, Anja Bye³, Arthur Kavanaugh⁴ and Mari Hoff⁵, ¹Faculty of Medicine, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Trondheim, Norway, ²Faculty of medicine, Department of public health and nursing, NTNU, Norwegian University of Science and Technology, Trondheim, Norway, ³NTNU, Norwegian University of Science and Technology, Trondheim, Norway, ⁴Medicine, University of California, San Diego, La Jolla, CA, ⁵Rheumatolgy, University Hospital, St. Olavs Hospital, NTNU, Trondheim, Norway
Background/Purpose: Patients with psoriatic arthritis (PsA) have a high disease burden with increased pain and more fatigue than the general population. Physical exercise is recommended…
Abstract Number: 2969 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF Inhibitors: 52-Week Results from a Phase 3 Study
Mark C. Genovese¹, Bernard Combe², Joel Kremer³, David Adams⁴, Chin Lee⁴, Lisa Kerr⁴ and Peter Nash⁵, ¹Stanford University Medical Center, Palo Alto, CA, ²Rheumatology, CHU Lapeyronie and Montpellier University, Montpellier, France, ³St. Peter's Hospital, Albany, NY, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵University of Queensland, Brisbane, Australia
Background/Purpose: Ixekizumab (IXE) is a high affinity monoclonal antibody that selectively targets interleukin-17A. In patients with active psoriatic arthritis (PsA) who had an inadequate response…
Abstract Number: 2970 • 2017 ACR/ARHP Annual Meeting
Inhibition of Radiographic Progression in Psoriatic Arthritis By Adalimumab Independent of the Control of Clinical Disease Activity
Robert B.M. Landewé¹, Christopher T. Ritchlin², Laura C Coates³, Daniel Aletaha⁴, Benoît Guérette⁵, Ying Zhang⁵, Fabiana Ganz⁶ and Maja Hojnik⁷, ¹University of Amsterdam, Amsterdam, Netherlands, ²Division of Allergy, Immunology and Rheumatology, School of Medicine and Dentistry, Division of Allergy, Immunology and Rheumatology, School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA, Rochester, NY, ³University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, Great Britain, ⁴Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie AG, Baar, Switzerland, ⁷AbbVie, Ljubljana, Slovenia
Background/Purpose : Patients (pts) with psoriatic arthritis (PsA) may experience structural damage and irreversible functional impairment if not treated appropriately. Treatment with TNF inhibitors in…
Abstract Number: 2971 • 2017 ACR/ARHP Annual Meeting
What Do Reduced 28 Joint Counts Miss in Patients with Psoriatic Arthritis?
Andreas Kerschbaumer¹, Josef S. Smolen^1,2 and Daniel Aletaha¹, ¹Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ²2nd Department of Medicine, Hietzing Hospital, Vienna, Austria
Background/Purpose: Clinical joint assessment by the rheumatologist is a key examination of patients with psoriatic arthritis (PSA). A clinically swollen joint is predicting subsequent joint…
Abstract Number: 2972 • 2017 ACR/ARHP Annual Meeting
Risk of Myocardial Infarction and Cerebrovascular Accident in Ankylosing Spondylitis: A General Population-Based Study
Anthony So¹, Jonathan Chan², Eric C. Sayre³ and J. Antonio Avina-Zubieta^3,4, ¹University of British Columbia, Vancouver, BC, Canada, ²Rheumatology, University of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Canada, Richmond, BC, Canada, ⁴Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: There is conflicting data on the risk of myocardial infarction (MI) and cerebrovascular accidents (CVA) in patients with Ankylosing Spondylitis (AS). This study attempts…
Abstract Number: 2973 • 2017 ACR/ARHP Annual Meeting
Detection of Clinical Signs of Arthritis and Subclinical Evidence of Inflammation in Psoriasis Patients with Risk for Arthritis: Value of Clinical Examination, Ultrasound and Fluorescence-Optical Imaging – Results from the Prospective Multicentre Xciting Study
Michaela Koehm¹, Tanja Rossmanith², Hans-Eckhard Langer³, Marina Backhaus⁴, Gerd R. Burmester⁵, Siegfried Wassenberg⁶, Benjamin Köhler⁶, Harald Burkhardt⁷ and Frank Behrens⁸, ¹Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt/Main, Germany, ²Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt, Germany, ³RHIO (Rheumatology, Immunology, Osteology) Duesseldorf, Duesseldorf, Germany, ⁴Rheumatology, Park-Klinik Weissensee, Berlin, Germany, ⁵Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, ⁶Rheumazentrum Ratingen, Ratingen, Germany, ⁷Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany, ⁸Clinical Research Rheumatology and Fraunhofer Institute IMETranslation, Goethe University, Frankfurt, Germany
Background/Purpose: Psoriasis (Pso) is one of the most common chronic inflammatory skin diseases in Europe. Psoriatic arthritis (PsA) is closely associated to Pso whereas the…
Abstract Number: 2974 • 2017 ACR/ARHP Annual Meeting
B Cell Binding Autoreactive VH4.34 Antibodies Are Specific to Lupus, Consist of Diverse Isotypes, and Are Associated with High Disease Activity and Lupus Nephritis
Scott Jenks¹, Joseph Marcus², Kevin Cashman¹ and Ignacio Sanz³, ¹Emory University School of Medicine and Lowance Center for Human Immunology, Atlanta, GA, ²San Antonio Uniformed Services Health Education Consortium, San Antonio, TX, ³Rheumatology and Lowance Center for Human Immunology, Emory University School of Medicine and Lowance Center for Human Immunology, Atlanta, GA
Background/Purpose: SLE is characterized by the dysregulation of humoral immunity including high levels of autoreactive IgG VH4.34 antibodies recognized by the rat anti-human idiotypic antibody…
Abstract Number: 2975 • 2017 ACR/ARHP Annual Meeting
Using Immune and Metabolic Phenotyping to Understand the Immunopathogenesis of Juvenile-Onset SLE and Stratify Patient Groups
George Robinson¹, Marsilio Adriani¹, Ines Pineda Torra², Yiannis Ioannou³ and Elizabeth Jury⁴, ¹Centre for Rheumatoloy Research, University College London, London, United Kingdom, ²Centre for Clinical Pharmacology, University College London, London, United Kingdom, ³Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ⁴Division of Medicine, Centre for Rheumatology Research, University College London, London, United Kingdom
Background/Purpose: Juvenile-onset systemic lupus erythematosus (JSLE) is an autoimmune disorder characterized by immune cell dysregulation, chronic inflammation and increased cardiovascular risk. Disease onset dominates mid-puberty…
Abstract Number: 2976 • 2017 ACR/ARHP Annual Meeting
Identification of Systemic Lupus Erythematosus Causal Risk Variant Candidates Spanning the UBE2L3 Haplotype
Jaanam Gopalakrishnan^1,2, Shaofeng Wang³, Yao Fu⁴, Satish Pasula¹, Ajay Nair¹, Mandi Wiley¹ and Patrick Gaffney^2,4, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Bethune Institute of Epigenetic Medicine, The First Hospital of Jilin University, Changchun, China, ⁴Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: SLE is a prototype systemic autoimmune disease. Genome-wide association studies have fine mapped a 67kb risk haplotype that spans the Ubiquitin-conjugating enzyme E2 L3…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].